Atarji Eman, Daous Yara M, Barefah Ahmed, Alahwal Hatem, Albaity Bushra, Hakami Nora Y, Alkhatabi Heba, Qadah Talal
Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.
Hematology Research Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.
Cancer Manag Res. 2025 Aug 22;17:1767-1776. doi: 10.2147/CMAR.S531465. eCollection 2025.
Classical Hodgkin Lymphoma (CHL) is a highly curable malignant disease of the lymphoid system. However, some patients may experience a clinical relapse. Biological marker expression may help to predict disease outcomes and guide salvage treatment options. CD20 expression occurs in approximately 30% of CHL cases. The clinical outcomes of patients with CHL and CD20 positivity remain controversial. Therefore, this study aimed to determine the prognostic value of CD20 expression in CHL patients.
This retrospective study included 52 patients with CHL between 2017-2023 with a median follow-up of 60 months (range: 24-72 months). Immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissue biopsies to assess CD20 expression. Chi-square and Fisher's exact tests were used to analyze categorical data and determine significant differences between the CD20 expression status groups. Overall survival (OS) and Progression-Free Survival (PFS) were assessed using Log rank test. Statistical significance was set at < 0.05.
Of 52 CHL patients, 11 (21.2%) showed CD20-positive Hodgkin Reed-Sternberg (HRS) cells. Most parameters showed no significant differences between the CD20-positive and CD20-negative groups, except for serum albumin level ( = 0.042). Log-rank analysis for OS and PFS revealed no significant differences between the groups.
CD20 expression in the HRS cells of CHL patients was not significantly associated with clinical outcomes. Further studies with larger patient populations and extended follow-up periods are required to validate these findings.
经典型霍奇金淋巴瘤（CHL）是一种淋巴系统的高治愈率恶性疾病。然而，一些患者可能会出现临床复发。生物标志物表达可能有助于预测疾病预后并指导挽救治疗方案。约30%的CHL病例中会出现CD20表达。CHL且CD20阳性患者的临床结局仍存在争议。因此，本研究旨在确定CD20表达在CHL患者中的预后价值。
这项回顾性研究纳入了2017年至2023年间的52例CHL患者，中位随访时间为60个月（范围：24 - 72个月）。对福尔马林固定、石蜡包埋的组织活检标本进行免疫组织化学检测，以评估CD20表达。采用卡方检验和Fisher精确检验分析分类数据，并确定CD20表达状态组之间的显著差异。使用对数秩检验评估总生存期（OS）和无进展生存期（PFS）。设定统计学显著性为<0.05。
在52例CHL患者中，11例（21.2%）显示霍奇金里德 - 斯腾伯格（HRS）细胞CD20阳性。除血清白蛋白水平（=0.042）外，大多数参数在CD20阳性组和CD20阴性组之间无显著差异。OS和PFS的对数秩分析显示两组之间无显著差异。
CHL患者HRS细胞中的CD20表达与临床结局无显著相关性。需要更大样本量患者及更长随访期的进一步研究来验证这些发现。
